Progress against RAS-driven cancers lauded at RAS Symposium, with more candidate treatments on the horizon
Researchers from around the world met in October to mark progress their field has made in developing drugs to treat cancers driven by the RAS oncogene, and to map out even more ways they can help cancer patients. “This is a great story about tackling an intractable disease that was said to be an impossible task,” said National Cancer Institute Director W. Kimryn Rathmell, M.D.